--News Direct--Skye Bioscience CEO Punit Dhillon joined Steve Darling from Proactive to share news announcing the company's uplisting of its common stock to the Nasdaq stock exchange, tradin… Read More
cemagraphics
Piper Sandler published the top 10 stocks with upwards and downwards daily percentage change as of Thursday.
In a technical research note, analysts led by Craig W. Johnson said… Read More
Personalized health screening from a “smart toilet” … how AI will revolutionize healthcare … transformative wellness care and bottom-line cost savings … how… Read More
This episode features an interview with Punit Dhillon, Chairman & CEO of Skye Bioscience, a pharmaceutical company developing proprietary molecules to treat diseases involving inflammato… Read More
Phase 1 clinical data to be released in conjunction with Investor DayThis document replaces and updates the previous version with the current OTCQB ticker for Skye Bioscience, Inc.San Diego… Read More
Skye completes dosing of final cohort of healthy volunteers in study of first-and-only-in-class proprietary cannabinoid derivativeSan Diego, California--(Newsfile Corp. - June 12, 2023) - Sk… Read More
Enrollment started for multiple ascending dose arm of Phase 1 studySan Diego, California--(Newsfile Corp. - April 4, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a… Read More
San Francisco, California--(Newsfile Corp. - February 2, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic c… Read More
San Diego, California--(Newsfile Corp. - January 31, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic canna… Read More
San Diego, California--(Newsfile Corp. - November 22, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cann… Read More
San Diego, California--(Newsfile Corp. - November 10, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cann… Read More
Additional capital from Arrangement Agreement expected to fund Skye's Phase 1 and 2 clinical studies of proprietary synthetic cannabinoid-derivative therapeutic targeting glaucomaSan Diego… Read More
From left: Colin Elliott, Sarah Rijkenberg, and Bismark Addo-Binney were the winners of the Ontario Tech’s Three Minute Thesis competition on March 23. Explaining complicated researc… Read More
Toronto, Ontario--(Newsfile Corp. - Le 11 novembre/November 2022) - Emerald Health Therapeutics, Inc. ("Emerald" or the "Company") announced today that its Plan of Arrangement with Sky… Read More
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 70+ key pharma and biotech companies are working on 70+ pipeline drugs in the Glaucoma therape… Read More
San Diego, Calif., March 03, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on… Read More
Company also provides bi-weekly MCTO status updateVancouver, British Columbia--(Newsfile Corp. - July 4, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald"… Read More
This year’s Investment U conference kicked off in partly cloudy San Diego on April 28. The day was commenced by Oxford Club CEO and founder of Investment U, Julia Guth. She opened up t… Read More